Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.
She discovered the world of the stock market in 1998. With her passion for innovation and digitalization, she focused on companies from the technology and healthcare sectors early on.
Analyzing fundamentals, business models and their scalability is as much her passion as thinking into complex future scenarios. Since 2019, the Hamburg resident has been organizing regular stock market roundtables. The author of the book "Entrepreneurial Investing" regularly attends international investment events to deepen and pass on her knowledge.
Kommentare von Juliane Zielonka
Kommentar von Juliane Zielonka vom 14.06.2024 | 06:40
CARDIOL THERAPEUTICS - Convincing Phase II study results, Wall Street sets price target at USD 9
Cardiovascular diseases have become one of the leading causes of death worldwide. With over 20 million deaths in 2021, they represent a severe global health emergency. What is particularly alarming is that up to 80% of heart attacks and strokes would be preventable if appropriate diagnosis, prevention, and treatment options were available across the board. This is where the Canadian company Cardiol Therapeutics comes in. The life sciences company focuses on the development of innovative therapies for the treatment of heart disease. The latest study results are now available and they are impressive. With a promising drug called CardiolRx™, which has already received FDA Orphan Drug Designation approval for the treatment of pericarditis, the Company is positioning itself in a market with huge sales potential. Analysts see a promising investment opportunity and expect a positive share price trend for the Company. One thing is already convincing: the results from the Phase II study, designed according to the highest medical standards and evidence-based science, are laying the foundation for future commercialization.
Zum Kommentar
Kommentar von Juliane Zielonka vom 22.11.2023 | 04:30
Stock news: Gloomy outlook for Bayer AG - Historic low after study failure and billion-euro lawsuit
Bayer's economic future is currently on shaky ground. The shares of the Group with its three pillars, Consumer Health, Pharma, and Agriculture, fell by almost 20% this week after a late-stage drug trial in the Pharma division was halted. In addition, a considerable compensation payment of EUR 1.5 billion in connection with the US glyphosate business has put the Leverkusen-based company in an unusually precarious position. The Company lost around EUR 7.7 billion in value in one day due to the price slide, and the share price fell to EUR 33, marking a historic low for Bayer AG shares since the financial crisis in 2009. Currently, the Bayer Group is only worth around EUR 32.77 billion. What needs to happen now for a possible way out of this dilemma? Would the often talked-about split-up of the Group be a solution for the further growth of the Group?
Zum Kommentar
Kommentar von Juliane Zielonka vom 26.07.2023 | 06:35
Share news: Biotech company Cardiol Therapeutics - Ongoing Phase II study provides optimism
Cardiovascular diseases have been in the spotlight, especially since the Corona pandemic. After receiving the COVID-19 vaccine, athletic and often young individuals experienced heart inflammation. When the heart muscle becomes inflamed, it is referred to as myocarditis. If the inflammation affects the heart's outer lining, known as the pericardium, it is called pericarditis. According to the US Centers for Disease Control and Prevention (CDC), most cases of myocarditis and pericarditis in male adolescents and young adults occurred within one week of the second dose of the mRNA COVID-19 vaccine. Cardiol Therapeutics is a life sciences company with a portfolio focused on combating heart diseases such as pericarditis, myocarditis and heart failure. The Company is in the clinical discovery and development stage of anti-inflammatory and antifibrotic therapies. Antifibrotic means that no scarring occurs during the healing process of human tissue. The experienced team is focusing on an active ingredient that occurs naturally in nature, cannabidiol.
Zum Kommentar
Kommentar von Juliane Zielonka vom 21.04.2023 | 05:01
Stock news: Bayer AG - Headwind expected at Annual General Meeting on April 28, 2023
In April, Bill Anderson of the United States took up his position on the Board of Management of Bayer AG. On June 1, 2023, he will be appointed CEO, succeeding Werner Baumann, who resigned one year earlier than the end of his contract due to pressure from dissatisfied investors. Anderson has enormous room for change, according to internal sources. It remains to be seen whether a breakup of the life science company would be a consequence of his appointment. Internally, such a move would lead to strong unrest and unsettle employees more than winning their trust in him as the new leader. The trained chemist is being diplomatic: He will spend the next two months "listening" and so far sees no consensus on the issue. Reporters learned this at Bayer's headquarters in Leverkusen, where Anderson gave a speech outlining his vision for the Company. He emphasized that he wants to focus on results and progress in science.
Zum Kommentar
Kommentar von Juliane Zielonka vom 10.02.2023 | 04:30
Stock news: Bayer AG - Change at the top gives investors hope
Shareholders of the agrochemicals and pharmaceuticals group Bayer made an unprecedented decision at the 2019 Annual Stockholders' Meeting: Werner Baumann, the incumbent Dax boss, was the first not to be discharged. Now - after four out of five years of his current contract - the way is clear for an external manager. Bill Anderson takes the helm as of April 1. Find out how the surprising change came about a year earlier than expected and what the consequences are for investors in this stock update.
Zum Kommentar
Kommentar von Juliane Zielonka vom 20.01.2023 | 06:01
Stock News: Cardiol Therapeutics - First patient enrolled in Phase II study
Cardiovascular disease is the most common cause of death worldwide, which claims at least 17.9 million lives each year. More than 4 out of 5 deaths from cardiovascular disease are due to heart attacks and strokes, 1/3 of which occur in people under 70. The most recent victim: Lisa Marie Presley. The daughter of music legend Elvis Presley lived to be only 54 years old and succumbed to cardiac arrest. Worldwide, 35% of women die from cardiovascular disease - making it the most common cause of death. Life sciences company Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is focused on the discovery and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. There is news, particularly in recurrent pericarditis.
Zum Kommentar
Kommentar von Juliane Zielonka vom 12.01.2023 | 05:30
Stock news: Bayer AG - Problem child Crop Science fuels split-up rumors
The J.P. Morgan Healthcare Conference, January 9 - 12, 2023, in San Francisco, is the largest and most informative healthcare investment conference, bringing together leaders in the industry. Emerging, fast-growing companies, innovative technology developers and investment community members also find a home here. Bayer Pharma Division Head and Board Member Stefan Oelrich is making investors' hearts beat faster with blockbuster-level new drug announcements and sales estimates. Four new drugs could generate sales of more than EUR 12 billion at peak times. Consumer Health also grew strongly on the back of increased self-medication. Can these two divisions pull Monsanto's beleaguered Crop Science division along? Early investors would like to see a change in leadership and are looking to split up the group to guarantee shareholder value.
Zum Kommentar
Kommentar von Juliane Zielonka vom 27.06.2022 | 05:21
Stock news: Bayer AG - Supreme Court ruling: No end to Monsanto lawsuits
On June 21, 2022, the US Supreme Court rejected an appeal by Bayer AG in the case brought by Californian Edwin Hardeman. Bayer AG sought to avoid billions of dollars in damages through the appeal in order to dismiss lawsuits brought by consumers like Hardeman. The Californian claims to have developed cancer from decades of using the weedkiller Roundup on his Bay Area property. Roundup is part of the product portfolio of Monsanto, which Bayer Group acquired in 2016. His lawsuit serves as an example for thousands of similar lawsuits. What does this mean for investors and private investors?
Zum Kommentar
Kommentar von Juliane Zielonka vom 20.04.2022 | 06:02
Bayer AG - The seed is growing
Last year went well for Bayer AG, with a consolidated net income of EUR 1 billion. In 2020, Bayer had posted a loss of EUR 10.5 billion. This was largely due to the formation of reserves for the Monsanto litigation. The Group also has to forfeit the loss of exclusivity rights to two of its most profitable pharmaceutical products. However, the seed business is picking up, as is the demand for pesticides. Thanks to its CropScience, Pharmaceuticals and Consumer Health divisions, Bayer has three mainstays. Back in the black, the Leverkusen-based company faces its next challenge: potential crisis effects from the Ukraine war and its consequences on the global economy have not yet been priced in.
Zum Kommentar